nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LRRK2—Crohn's disease	0.286	0.398	CbGaD
Ruxolitinib—TYK2—Crohn's disease	0.217	0.301	CbGaD
Ruxolitinib—JAK2—Crohn's disease	0.217	0.301	CbGaD
Ruxolitinib—RET—enteric nervous system—Crohn's disease	0.00944	0.11	CbGeAlD
Ruxolitinib—Myelosuppression—Mercaptopurine—Crohn's disease	0.00279	0.094	CcSEcCtD
Ruxolitinib—LTK—mouth—Crohn's disease	0.00242	0.0281	CbGeAlD
Ruxolitinib—Tuberculosis—Prednisone—Crohn's disease	0.00206	0.0693	CcSEcCtD
Ruxolitinib—PRKG2—smooth muscle tissue—Crohn's disease	0.00188	0.0218	CbGeAlD
Ruxolitinib—Myelosuppression—Azathioprine—Crohn's disease	0.00166	0.056	CcSEcCtD
Ruxolitinib—PLK1—skin of body—Crohn's disease	0.00166	0.0193	CbGeAlD
Ruxolitinib—PLK1—mammalian vulva—Crohn's disease	0.00152	0.0176	CbGeAlD
Ruxolitinib—PRKG2—digestive system—Crohn's disease	0.00148	0.0172	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—Crohn's disease	0.00135	0.0156	CbGeAlD
Ruxolitinib—PLK1—digestive system—Crohn's disease	0.00133	0.0154	CbGeAlD
Ruxolitinib—PLK3—mammalian vulva—Crohn's disease	0.00126	0.0147	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—Crohn's disease	0.00118	0.0137	CbGeAlD
Ruxolitinib—JAK1—epithelium—Crohn's disease	0.00112	0.013	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—Crohn's disease	0.00108	0.0125	CbGeAlD
Ruxolitinib—JAK1—skin of body—Crohn's disease	0.00106	0.0124	CbGeAlD
Ruxolitinib—Herpes zoster—Azathioprine—Crohn's disease	0.00104	0.0349	CcSEcCtD
Ruxolitinib—MARK2—digestive system—Crohn's disease	0.00101	0.0117	CbGeAlD
Ruxolitinib—JAK1—mammalian vulva—Crohn's disease	0.00097	0.0113	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—Crohn's disease	0.00097	0.0113	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—Crohn's disease	0.000967	0.0112	CbGeAlD
Ruxolitinib—ROCK1—epithelium—Crohn's disease	0.000963	0.0112	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—Crohn's disease	0.000947	0.011	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—Crohn's disease	0.000928	0.0108	CbGeAlD
Ruxolitinib—DAPK2—mammalian vulva—Crohn's disease	0.000926	0.0108	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—Crohn's disease	0.000902	0.0105	CbGeAlD
Ruxolitinib—BMPR2—skin of body—Crohn's disease	0.00089	0.0103	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—Crohn's disease	0.00087	0.0101	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—Crohn's disease	0.000867	0.0101	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—Crohn's disease	0.000862	0.01	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—Crohn's disease	0.000861	0.01	CbGeAlD
Ruxolitinib—JAK3—digestive system—Crohn's disease	0.000856	0.00995	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—Crohn's disease	0.000856	0.00995	CbGeAlD
Ruxolitinib—JAK1—digestive system—Crohn's disease	0.000851	0.00989	CbGeAlD
Ruxolitinib—DCLK1—digestive system—Crohn's disease	0.000851	0.00989	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—Crohn's disease	0.000808	0.00939	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—Crohn's disease	0.000804	0.00934	CbGeAlD
Ruxolitinib—STK16—digestive system—Crohn's disease	0.000799	0.00928	CbGeAlD
Ruxolitinib—HIPK2—digestive system—Crohn's disease	0.000794	0.00923	CbGeAlD
Ruxolitinib—PRKCE—lymph node—Crohn's disease	0.00079	0.00918	CbGeAlD
Ruxolitinib—Pancytopenia—Mercaptopurine—Crohn's disease	0.000781	0.0263	CcSEcCtD
Ruxolitinib—NUAK2—mammalian vulva—Crohn's disease	0.000776	0.00901	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—Crohn's disease	0.000765	0.00889	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—Crohn's disease	0.000759	0.00882	CbGeAlD
Ruxolitinib—PLK1—lymph node—Crohn's disease	0.000759	0.00882	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—Crohn's disease	0.000742	0.00862	CbGeAlD
Ruxolitinib—ROCK1—digestive system—Crohn's disease	0.000733	0.00851	CbGeAlD
Ruxolitinib—MKNK2—epithelium—Crohn's disease	0.00073	0.00848	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—Crohn's disease	0.000726	0.00843	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—Crohn's disease	0.000724	0.00841	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—Crohn's disease	0.000721	0.00837	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—Crohn's disease	0.00072	0.00836	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—Crohn's disease	0.000713	0.00828	CbGeAlD
Ruxolitinib—RET—epithelium—Crohn's disease	0.000712	0.00827	CbGeAlD
Ruxolitinib—BMPR2—digestive system—Crohn's disease	0.000712	0.00827	CbGeAlD
Ruxolitinib—TYK2—skin of body—Crohn's disease	0.000703	0.00817	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—Crohn's disease	0.000703	0.00817	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—Crohn's disease	0.000703	0.00817	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000693	0.0233	CcSEcCtD
Ruxolitinib—JAK2—epithelium—Crohn's disease	0.000673	0.00782	CbGeAlD
Ruxolitinib—MAP3K7—mammalian vulva—Crohn's disease	0.000653	0.00759	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—Crohn's disease	0.000648	0.00753	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—Crohn's disease	0.000642	0.00745	CbGeAlD
Ruxolitinib—JAK2—skin of body—Crohn's disease	0.00064	0.00744	CbGeAlD
Ruxolitinib—CAMK2G—digestive system—Crohn's disease	0.000637	0.0074	CbGeAlD
Ruxolitinib—PLK3—lymph node—Crohn's disease	0.000633	0.00736	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—Crohn's disease	0.000633	0.00736	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—Crohn's disease	0.000633	0.00736	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—Crohn's disease	0.000617	0.00717	CbGeAlD
Ruxolitinib—LTK—lymph node—Crohn's disease	0.000612	0.00711	CbGeAlD
Ruxolitinib—CAMK1—lymph node—Crohn's disease	0.000593	0.00688	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—Crohn's disease	0.000586	0.0068	CbGeAlD
Ruxolitinib—JAK2—mammalian vulva—Crohn's disease	0.000584	0.00678	CbGeAlD
Ruxolitinib—MARK2—lymph node—Crohn's disease	0.000575	0.00668	CbGeAlD
Ruxolitinib—Malnutrition—Mercaptopurine—Crohn's disease	0.000573	0.0193	CcSEcCtD
Ruxolitinib—TYK2—lymphoid tissue—Crohn's disease	0.00057	0.00662	CbGeAlD
Ruxolitinib—TYK2—digestive system—Crohn's disease	0.000563	0.00654	CbGeAlD
Ruxolitinib—MAP3K3—mammalian vulva—Crohn's disease	0.000563	0.00654	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—Crohn's disease	0.000562	0.00653	CbGeAlD
Ruxolitinib—MKNK2—digestive system—Crohn's disease	0.000555	0.00645	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—Crohn's disease	0.000548	0.00637	CbGeAlD
Ruxolitinib—RET—digestive system—Crohn's disease	0.000542	0.00629	CbGeAlD
Ruxolitinib—TAOK2—lymph node—Crohn's disease	0.000532	0.00618	CbGeAlD
Ruxolitinib—Anaemia—Mercaptopurine—Crohn's disease	0.000529	0.0178	CcSEcCtD
Ruxolitinib—JAK2—lymphoid tissue—Crohn's disease	0.000518	0.00602	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000516	0.0174	CcSEcCtD
Ruxolitinib—TAOK3—mammalian vulva—Crohn's disease	0.000513	0.00596	CbGeAlD
Ruxolitinib—JAK2—digestive system—Crohn's disease	0.000512	0.00595	CbGeAlD
Ruxolitinib—JAK3—lymph node—Crohn's disease	0.000489	0.00568	CbGeAlD
Ruxolitinib—JAK1—lymph node—Crohn's disease	0.000486	0.00565	CbGeAlD
Ruxolitinib—DCLK1—lymph node—Crohn's disease	0.000486	0.00565	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000484	0.0163	CcSEcCtD
Ruxolitinib—PLK4—lymph node—Crohn's disease	0.000483	0.00561	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—Crohn's disease	0.000474	0.00551	CbGeAlD
Ruxolitinib—PHKG2—lymph node—Crohn's disease	0.000472	0.00548	CbGeAlD
Ruxolitinib—Pancytopenia—Azathioprine—Crohn's disease	0.000465	0.0157	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—Crohn's disease	0.000464	0.00539	CbGeAlD
Ruxolitinib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000458	0.0154	CcSEcCtD
Ruxolitinib—STK16—lymph node—Crohn's disease	0.000456	0.0053	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—Crohn's disease	0.000455	0.00529	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000455	0.0153	CcSEcCtD
Ruxolitinib—Skin disorder—Mercaptopurine—Crohn's disease	0.000454	0.0153	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—Crohn's disease	0.000454	0.00527	CbGeAlD
Ruxolitinib—TAOK3—digestive system—Crohn's disease	0.00045	0.00523	CbGeAlD
Ruxolitinib—Infestation—Azathioprine—Crohn's disease	0.000437	0.0147	CcSEcCtD
Ruxolitinib—Infestation NOS—Azathioprine—Crohn's disease	0.000437	0.0147	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—Crohn's disease	0.000436	0.00506	CbGeAlD
Ruxolitinib—CLK2—lymph node—Crohn's disease	0.000432	0.00502	CbGeAlD
Ruxolitinib—Contusion—Prednisone—Crohn's disease	0.000431	0.0145	CcSEcCtD
Ruxolitinib—Pancytopenia—Mesalazine—Crohn's disease	0.000424	0.0143	CcSEcCtD
Ruxolitinib—Neutropenia—Mesalazine—Crohn's disease	0.000417	0.014	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000413	0.0139	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—Crohn's disease	0.000408	0.00474	CbGeAlD
Ruxolitinib—BMPR2—lymph node—Crohn's disease	0.000407	0.00472	CbGeAlD
Ruxolitinib—Weight increased—Mesalazine—Crohn's disease	0.000406	0.0137	CcSEcCtD
Ruxolitinib—Weight decreased—Mesalazine—Crohn's disease	0.000404	0.0136	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000404	0.0136	CcSEcCtD
Ruxolitinib—Infestation NOS—Mesalazine—Crohn's disease	0.000398	0.0134	CcSEcCtD
Ruxolitinib—Infestation—Mesalazine—Crohn's disease	0.000398	0.0134	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000398	0.0134	CcSEcCtD
Ruxolitinib—Haemoglobin—Azathioprine—Crohn's disease	0.000394	0.0133	CcSEcCtD
Ruxolitinib—Haemorrhage—Azathioprine—Crohn's disease	0.000392	0.0132	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—Crohn's disease	0.000389	0.00451	CbGeAlD
Ruxolitinib—Urinary tract infection—Mesalazine—Crohn's disease	0.000387	0.013	CcSEcCtD
Ruxolitinib—Haematuria—Mesalazine—Crohn's disease	0.000379	0.0128	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000376	0.0127	CcSEcCtD
Ruxolitinib—Epistaxis—Mesalazine—Crohn's disease	0.000375	0.0126	CcSEcCtD
Ruxolitinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000369	0.0124	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—Crohn's disease	0.000364	0.00423	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—Crohn's disease	0.000364	0.00423	CbGeAlD
Ruxolitinib—LRRK2—lymph node—Crohn's disease	0.000361	0.00419	CbGeAlD
Ruxolitinib—Haemoglobin—Mesalazine—Crohn's disease	0.000359	0.0121	CcSEcCtD
Ruxolitinib—Haemorrhage—Mesalazine—Crohn's disease	0.000357	0.012	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—Crohn's disease	0.00033	0.00384	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—Crohn's disease	0.000327	0.0038	CbGeAlD
Ruxolitinib—TYK2—lymph node—Crohn's disease	0.000321	0.00373	CbGeAlD
Ruxolitinib—MKNK2—lymph node—Crohn's disease	0.000317	0.00369	CbGeAlD
Ruxolitinib—IRAK1—lymph node—Crohn's disease	0.000317	0.00369	CbGeAlD
Ruxolitinib—Anaemia—Azathioprine—Crohn's disease	0.000315	0.0106	CcSEcCtD
Ruxolitinib—RET—lymph node—Crohn's disease	0.000309	0.00359	CbGeAlD
Ruxolitinib—Flatulence—Mesalazine—Crohn's disease	0.000306	0.0103	CcSEcCtD
Ruxolitinib—JAK2—lymph node—Crohn's disease	0.000292	0.0034	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000289	0.00971	CcSEcCtD
Ruxolitinib—Anaemia—Mesalazine—Crohn's disease	0.000287	0.00967	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—Crohn's disease	0.000282	0.00327	CbGeAlD
Ruxolitinib—Infection—Azathioprine—Crohn's disease	0.000277	0.00931	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000273	0.00919	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000273	0.00918	CcSEcCtD
Ruxolitinib—Skin disorder—Azathioprine—Crohn's disease	0.00027	0.0091	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000263	0.00884	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—Crohn's disease	0.000257	0.00298	CbGeAlD
Ruxolitinib—Infection—Mesalazine—Crohn's disease	0.000252	0.00848	CcSEcCtD
Ruxolitinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000249	0.00837	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000248	0.00836	CcSEcCtD
Ruxolitinib—Skin disorder—Mesalazine—Crohn's disease	0.000246	0.00829	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000241	0.00811	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00024	0.00809	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—Crohn's disease	0.000221	0.00743	CcSEcCtD
Ruxolitinib—Body temperature increased—Azathioprine—Crohn's disease	0.00022	0.00741	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000219	0.00737	CcSEcCtD
Ruxolitinib—Fatigue—Mesalazine—Crohn's disease	0.000219	0.00736	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—Crohn's disease	0.000215	0.00723	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—Crohn's disease	0.000214	0.00719	CcSEcCtD
Ruxolitinib—Body temperature increased—Mesalazine—Crohn's disease	0.000201	0.00675	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—Crohn's disease	0.00019	0.00639	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—Crohn's disease	0.000189	0.00636	CcSEcCtD
Ruxolitinib—Dizziness—Azathioprine—Crohn's disease	0.000184	0.0062	CcSEcCtD
Ruxolitinib—Asthenia—Mesalazine—Crohn's disease	0.000182	0.00613	CcSEcCtD
Ruxolitinib—Pruritus—Mesalazine—Crohn's disease	0.000179	0.00604	CcSEcCtD
Ruxolitinib—Headache—Azathioprine—Crohn's disease	0.000174	0.00587	CcSEcCtD
Ruxolitinib—Dizziness—Mesalazine—Crohn's disease	0.000168	0.00565	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—Crohn's disease	0.000164	0.00553	CcSEcCtD
Ruxolitinib—Headache—Mesalazine—Crohn's disease	0.000159	0.00535	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—Crohn's disease	0.000152	0.00512	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000139	0.00468	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—Crohn's disease	0.000137	0.00159	CbGeAlD
Ruxolitinib—Infection—Prednisone—Crohn's disease	0.000133	0.00449	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—Crohn's disease	0.000132	0.00443	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—Crohn's disease	0.00013	0.00439	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—Crohn's disease	0.000116	0.00389	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—Crohn's disease	0.000106	0.00357	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—Crohn's disease	9.63e-05	0.00324	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—Crohn's disease	9.5e-05	0.0032	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—Crohn's disease	8.88e-05	0.00299	CcSEcCtD
Ruxolitinib—Headache—Prednisone—Crohn's disease	8.41e-05	0.00283	CcSEcCtD
Ruxolitinib—PRKCE—Innate Immune System—IL6—Crohn's disease	6.82e-06	4.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IFNG—Crohn's disease	6.81e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SMAD3—Crohn's disease	6.8e-06	4.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1B—Crohn's disease	6.79e-06	4.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CD4—Crohn's disease	6.78e-06	4.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—JAK2—Crohn's disease	6.78e-06	4.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SOCS1—Crohn's disease	6.77e-06	4.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2RA—Crohn's disease	6.76e-06	4.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CD4—Crohn's disease	6.76e-06	4.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL18—Crohn's disease	6.75e-06	4.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—Crohn's disease	6.73e-06	4.11e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD4—Crohn's disease	6.73e-06	4.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL6—Crohn's disease	6.72e-06	4.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTGER4—Crohn's disease	6.7e-06	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL3—Crohn's disease	6.69e-06	4.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RBX1—Crohn's disease	6.67e-06	4.08e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—JAK2—Crohn's disease	6.67e-06	4.07e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—STAT3—Crohn's disease	6.66e-06	4.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SOCS1—Crohn's disease	6.66e-06	4.07e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—IL6—Crohn's disease	6.6e-06	4.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD4—Crohn's disease	6.57e-06	4.02e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CD4—Crohn's disease	6.56e-06	4.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—JAK2—Crohn's disease	6.54e-06	4e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CXCL8—Crohn's disease	6.53e-06	3.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—UBE2D1—Crohn's disease	6.53e-06	3.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—Crohn's disease	6.52e-06	3.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTGER4—Crohn's disease	6.5e-06	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RASGRP1—Crohn's disease	6.47e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—ALB—Crohn's disease	6.46e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—TYK2—Crohn's disease	6.46e-06	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD79A—Crohn's disease	6.45e-06	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IFNG—Crohn's disease	6.42e-06	3.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TYK2—Crohn's disease	6.42e-06	3.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—Crohn's disease	6.41e-06	3.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2RA—Crohn's disease	6.37e-06	3.89e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—TYK2—Crohn's disease	6.35e-06	3.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TAB1—Crohn's disease	6.33e-06	3.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—Crohn's disease	6.32e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	6.32e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—Crohn's disease	6.3e-06	3.85e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2RA—Crohn's disease	6.29e-06	3.84e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—STAT3—Crohn's disease	6.26e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—Crohn's disease	6.25e-06	3.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NOD2—Crohn's disease	6.22e-06	3.8e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—Crohn's disease	6.22e-06	3.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—UBE2D1—Crohn's disease	6.21e-06	3.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—Crohn's disease	6.2e-06	3.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CXCL8—Crohn's disease	6.19e-06	3.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2RA—Crohn's disease	6.18e-06	3.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SMAD3—Crohn's disease	6.16e-06	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—JAK2—Crohn's disease	6.16e-06	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	6.1e-06	3.73e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CXCL8—Crohn's disease	6.09e-06	3.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—Crohn's disease	6.07e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—JAK2—Crohn's disease	6.06e-06	3.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—UBE2D1—Crohn's disease	6.03e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RIPK2—Crohn's disease	6.03e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CRP—Crohn's disease	6.01e-06	3.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2RA—Crohn's disease	5.99e-06	3.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—STAT3—Crohn's disease	5.93e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—TYK2—Crohn's disease	5.9e-06	3.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL3—Crohn's disease	5.88e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SOCS1—Crohn's disease	5.86e-06	3.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—UBE2D1—Crohn's disease	5.85e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RIPK2—Crohn's disease	5.85e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SMAD3—Crohn's disease	5.85e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CRP—Crohn's disease	5.83e-06	3.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—Crohn's disease	5.8e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR6—Crohn's disease	5.77e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TLR4—Crohn's disease	5.76e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SMAD3—Crohn's disease	5.75e-06	3.51e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—Crohn's disease	5.73e-06	3.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL3—Crohn's disease	5.7e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—STAT3—Crohn's disease	5.69e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RASGRP1—Crohn's disease	5.68e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RIPK2—Crohn's disease	5.67e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—TYK2—Crohn's disease	5.67e-06	3.46e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—STAT3—Crohn's disease	5.67e-06	3.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CRP—Crohn's disease	5.65e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—Crohn's disease	5.65e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2RA—Crohn's disease	5.65e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—JAK2—Crohn's disease	5.63e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CXCL8—Crohn's disease	5.62e-06	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—Crohn's disease	5.61e-06	3.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—TLR4—Crohn's disease	5.59e-06	3.41e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL3—Crohn's disease	5.53e-06	3.38e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CXCL8—Crohn's disease	5.53e-06	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNG—Crohn's disease	5.52e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ICAM1—Crohn's disease	5.52e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RASGRP1—Crohn's disease	5.52e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—Crohn's disease	5.52e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TYK2—Crohn's disease	5.45e-06	3.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TLR4—Crohn's disease	5.42e-06	3.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2RA—Crohn's disease	5.41e-06	3.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ICAM1—Crohn's disease	5.36e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RASGRP1—Crohn's disease	5.35e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—Crohn's disease	5.33e-06	3.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2RA—Crohn's disease	5.32e-06	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL18—Crohn's disease	5.28e-06	3.22e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TYK2—Crohn's disease	5.25e-06	3.21e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—STAT3—Crohn's disease	5.25e-06	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RBX1—Crohn's disease	5.21e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—STAT3—Crohn's disease	5.21e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ICAM1—Crohn's disease	5.2e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—JAK2—Crohn's disease	5.2e-06	3.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SOCS1—Crohn's disease	5.15e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—Crohn's disease	5.13e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2RA—Crohn's disease	5.13e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—Crohn's disease	5.12e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—STAT3—Crohn's disease	5.09e-06	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTGER4—Crohn's disease	5.08e-06	3.1e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—JAK2—Crohn's disease	5.01e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SOCS1—Crohn's disease	5e-06	3.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—Crohn's disease	4.95e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—Crohn's disease	4.94e-06	3.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—Crohn's disease	4.93e-06	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—Crohn's disease	4.93e-06	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—Crohn's disease	4.89e-06	2.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—Crohn's disease	4.86e-06	2.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SOCS1—Crohn's disease	4.85e-06	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—STAT3—Crohn's disease	4.8e-06	2.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2RA—Crohn's disease	4.68e-06	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SMAD3—Crohn's disease	4.67e-06	2.85e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—Crohn's disease	4.65e-06	2.84e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CXCL8—Crohn's disease	4.57e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—UBE2D1—Crohn's disease	4.57e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—JAK2—Crohn's disease	4.55e-06	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—STAT3—Crohn's disease	4.49e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TYK2—Crohn's disease	4.49e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMAD3—Crohn's disease	4.45e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RIPK2—Crohn's disease	4.43e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TYK2—Crohn's disease	4.43e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—Crohn's disease	4.42e-06	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—Crohn's disease	4.4e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—Crohn's disease	4.38e-06	2.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—Crohn's disease	4.35e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL3—Crohn's disease	4.32e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMAD3—Crohn's disease	4.32e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—JAK2—Crohn's disease	4.28e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TLR4—Crohn's disease	4.24e-06	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JAK2—Crohn's disease	4.23e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TYK2—Crohn's disease	4.22e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—Crohn's disease	4.2e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMAD3—Crohn's disease	4.19e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RASGRP1—Crohn's disease	4.18e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JAK2—Crohn's disease	4.15e-06	2.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CXCL8—Crohn's disease	4.15e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—Crohn's disease	4.14e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—STAT3—Crohn's disease	4.13e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2RA—Crohn's disease	4.12e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—Crohn's disease	4.08e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ICAM1—Crohn's disease	4.06e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—Crohn's disease	4.06e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JAK2—Crohn's disease	4.03e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2RA—Crohn's disease	4e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—Crohn's disease	3.97e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—Crohn's disease	3.96e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—Crohn's disease	3.96e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—Crohn's disease	3.94e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—Crohn's disease	3.89e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	3.88e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2RA—Crohn's disease	3.88e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL8—Crohn's disease	3.86e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—JAK2—Crohn's disease	3.84e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—Crohn's disease	3.82e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TYK2—Crohn's disease	3.81e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—Crohn's disease	3.81e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SOCS1—Crohn's disease	3.79e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—Crohn's disease	3.77e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TYK2—Crohn's disease	3.75e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—Crohn's disease	3.75e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—Crohn's disease	3.68e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—Crohn's disease	3.67e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—Crohn's disease	3.67e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—Crohn's disease	3.66e-06	2.23e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—Crohn's disease	3.64e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JAK2—Crohn's disease	3.64e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—Crohn's disease	3.64e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—Crohn's disease	3.64e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—TYK2—Crohn's disease	3.61e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—Crohn's disease	3.61e-06	2.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JAK2—Crohn's disease	3.58e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—Crohn's disease	3.56e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—Crohn's disease	3.55e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—Crohn's disease	3.53e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—Crohn's disease	3.46e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—Crohn's disease	3.35e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—Crohn's disease	3.32e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	3.3e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TYK2—Crohn's disease	3.3e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMAD3—Crohn's disease	3.27e-06	2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—Crohn's disease	3.27e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—Crohn's disease	3.16e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—Crohn's disease	3.14e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—Crohn's disease	3.14e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—Crohn's disease	3.14e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—Crohn's disease	3.11e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—Crohn's disease	3.1e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—Crohn's disease	3.09e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—Crohn's disease	3.05e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TYK2—Crohn's disease	3.05e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2RA—Crohn's disease	3.03e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—Crohn's disease	2.98e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—Crohn's disease	2.96e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TYK2—Crohn's disease	2.9e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—Crohn's disease	2.89e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—Crohn's disease	2.82e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—Crohn's disease	2.77e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JAK2—Crohn's disease	2.77e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—Crohn's disease	2.76e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—Crohn's disease	2.76e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—Crohn's disease	2.74e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TYK2—Crohn's disease	2.73e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JAK2—Crohn's disease	2.69e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—Crohn's disease	2.67e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—Crohn's disease	2.66e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—Crohn's disease	2.63e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JAK2—Crohn's disease	2.61e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FADS1—Crohn's disease	2.57e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—Crohn's disease	2.57e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—Crohn's disease	2.53e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—Crohn's disease	2.45e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX4—Crohn's disease	2.41e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—Crohn's disease	2.38e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—Crohn's disease	2.33e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCKR—Crohn's disease	2.33e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—Crohn's disease	2.31e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—Crohn's disease	2.19e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—Crohn's disease	2.17e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TYK2—Crohn's disease	2.13e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—Crohn's disease	2.13e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—Crohn's disease	2.13e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—Crohn's disease	2.07e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—Crohn's disease	2.03e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—Crohn's disease	1.97e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—Crohn's disease	1.97e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—Crohn's disease	1.91e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—Crohn's disease	1.87e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—Crohn's disease	1.86e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—Crohn's disease	1.83e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—Crohn's disease	1.77e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—Crohn's disease	1.61e-06	9.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—Crohn's disease	1.49e-06	9.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—Crohn's disease	1.49e-06	9.1e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—Crohn's disease	1.42e-06	8.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—Crohn's disease	1.38e-06	8.41e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—Crohn's disease	1.34e-06	8.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—Crohn's disease	1.04e-06	6.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—Crohn's disease	7.4e-07	4.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	6.47e-07	3.96e-06	CbGpPWpGaD
